What FDA’s 2026 GLP-1 safety crackdown means for patients using compounded semaglutide or tirzepatide

If you use semaglutide or tirzepatide for diabetes or weight management, the FDA’s 2026 safety actions do not mean everyone should stop treatment. The agency’s warnings are aimed at non-FDA-approved compounded products and illegally marketed versions, not at patients who are using FDA-approved medicines such as Ozempic, Wegovy, Mounjaro, or Zepbound through normal prescribing and pharmacy channels.

That distinction matters, because many patients have been told or led to believe that a compounded product is basically the same as a brand-name GLP-1 drug. The FDA says that is not true. Compounded drugs are not reviewed by the agency the way approved drugs are for safety, effectiveness, and quality before they are sold.

Why the FDA acted in 2026

In a February 6, 2026 statement, the FDA said it planned to restrict GLP-1 ingredients intended for use in mass-marketed, non-FDA-approved compounded products. On March 3, 2026, the agency said it had sent warning letters to 30 telehealth companies over false or misleading claims about compounded GLP-1s.

According to the FDA, some promotions made compounded products sound like generic versions of approved drugs, implied they were the same as FDA-approved medicines, or blurred who was actually making the product. The agency also said companies cannot claim that compounded products use the same active ingredient as approved drugs or that they are clinically proven in the same way.

This is why many readers are confused: the warning is about how some products were being made, sold, and advertised, not a recall of approved GLP-1 brands.

Which products the crackdown does and does not target

The main group affected is people who are using or considering compounded semaglutide or compounded tirzepatide, especially if the product came through an online seller, a heavily advertised telehealth offer, or a source that did not clearly identify the dispensing pharmacy.

If you receive an FDA-approved GLP-1 in its original branded pen from a licensed pharmacy with a lawful prescription, these alerts are not telling you that your routine medicine is suddenly unsafe. But if your product was mixed by a compounding pharmacy, shipped in a vial, measured with a syringe, relabeled under a company name, or marketed as a cheaper version of a brand-name GLP-1, it is worth checking exactly what you have.

That does not mean every compounded drug is illegal or counterfeit. Compounding can be appropriate in limited situations, such as when a patient has a medical need that an approved product cannot meet. But the FDA, the American Diabetes Association, and other experts have all warned that non-FDA-approved compounded GLP-1 and similar drugs should not be treated as interchangeable with approved products.

The safety problems the FDA says patients should know about

The FDA’s patient safety page highlights several concerns:

Dosing errors. The agency says it has received multiple reports of dosing mistakes with compounded semaglutide, including some that required hospitalization. Problems included patients measuring the wrong amount and clinicians or sellers using incorrect calculations.
Doses outside approved labeling. Some reports involved people receiving doses higher than the FDA-approved titration schedules or increasing too quickly.
Salt forms and other ingredients. The FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide used in approved products, and the agency has not established that they have the same properties.
Counterfeit products. The FDA continues to warn about counterfeit Ozempic and says fake products may contain the wrong ingredient, too much drug, too little drug, or none at all.
Illegal online sales. The agency says some products sold online may be counterfeit, contaminated, or falsely labeled for “research purposes” even though they are being used by consumers.
Shipping and storage problems. Injectable GLP-1 medicines generally require refrigeration. The FDA says some compounded products have arrived warm or with inadequate cooling, which can affect quality.

The FDA has also said it has received hundreds of adverse event reports tied to compounded semaglutide and tirzepatide. That number does not tell us how often harm happens, and it does not prove every reported event was caused by the drug. In fact, the agency notes these reports are likely undercounted because many state-licensed pharmacies are not required to send adverse event reports to the FDA. Still, the reports were serious enough to trigger stronger warnings.

Why compounded GLP-1 use grew, and what changed

This problem did not appear out of nowhere. Demand for GLP-1 medicines surged during the past several years, and shortages pushed some patients toward compounded versions when approved products were hard to find or too expensive. A cross-sectional study published in JAMA Health Forum in January 2025 reviewed 79 websites selling compounded GLP-1s and found many did not clearly disclose that the products were compounded or not FDA-approved. Some also used language that suggested FDA approval. One important limitation: search results varied by location, and researchers reviewed full websites, which may not reflect exactly what every shopper sees.

The supply picture later changed. The FDA said the tirzepatide injection shortage was resolved on December 19, 2024, and the semaglutide injection shortage was resolved on February 21, 2025, though the agency noted that intermittent local supply disruptions could still happen as products move through the supply chain. As supply stabilized, the legal room for making copies of shortage drugs narrowed, and the agency’s enforcement posture became more aggressive.

AP also reported in February 2026 that the market was shifting quickly after the FDA’s action, with at least one major telehealth company backing away from a planned off-brand GLP-1 pill. For patients, that means offers, refill programs, and product labels may be changing fast.

How to tell whether your product is FDA-approved, compounded, or suspicious

If you are not sure what you are taking, ask these questions before your next refill:

Is this product FDA-approved, or is it compounded?
What is the exact drug name on the label? Look closely for terms like semaglutide sodium or semaglutide acetate.
Was it dispensed by a state-licensed pharmacy?
Is there a licensed prescriber and a licensed pharmacist involved?
Does the label clearly show the dose, concentration, and how much to inject?
Are you using a prefilled pen, or are you measuring doses yourself with a vial and syringe?
Did the medicine arrive cold if it needed refrigeration?
Does the packaging look professional and consistent, or are there spelling mistakes, strange return addresses, or vague branding?
Is the product being sold for “research use” or “not for human consumption”? If so, do not use it.

If any of those answers are unclear, contact your pharmacist or prescribing clinician before you take the next dose.

Common side effects versus warning signs

Some side effects can happen even with FDA-approved semaglutide or tirzepatide. MedlinePlus lists nausea, vomiting, diarrhea, constipation, stomach pain, and heartburn among the more common problems with semaglutide injection. Those symptoms can be unpleasant but are often managed by dose adjustments, slower titration, hydration, and follow-up with your clinician.

More urgent symptoms deserve prompt medical advice. Contact a clinician right away if you have:

ongoing upper abdominal pain, especially if it spreads to the back
severe or persistent vomiting or diarrhea
yellowing of the skin or eyes, fever, or pale or clay-colored stools
decreased urination or swelling in the legs or feet
vision changes
rash, swelling of the face or throat, trouble breathing, fainting, or severe dizziness
confusion about how much to inject or concern that you may have taken the wrong dose

If you think you used the wrong amount, do not simply “balance it out” with another dose. Call your clinician, pharmacist, or Poison Control for guidance.

What to do before stopping, switching, or refilling treatment

Do not stop abruptly, switch doses, or refill from a new website on your own because of a headline or social media post. GLP-1 medicines are usually started low and increased gradually. A sudden change in product strength, measuring instructions, or refill source can create its own risks.

Before making any change, ask your clinician or pharmacist:

Am I on an FDA-approved product or a compounded one?
If this source is no longer appropriate, what is the safest alternative for me?
Do I need a new prescription, prior authorization, or a different pharmacy?
How should I handle missed doses or leftover medication?
What symptoms should trigger an urgent call?

If cost pushed you toward a compounded product, say that plainly. Access and affordability are real issues, and your care team may be able to help with coverage appeals, alternative approved drugs, manufacturer programs, or different dispensing options.

What this means for readers

The practical message is simple: do not assume a compounded or online GLP-1 product is the same as an FDA-approved medicine. The FDA’s 2026 crackdown is focused on nonapproved compounded and illegally marketed products that may carry extra risks from dosing problems, questionable ingredients, counterfeit supply, or misleading advertising.

If your prescription came through an online service or arrived in a form that looks different from a brand-name GLP-1, now is a good time to verify exactly what it is, who filled it, and how it should be used. And if you are unsure, do not guess with the next injection. Call your pharmacist or your own clinician first.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.